NICE Issues Two Major 2025 Approvals: Vutrisiran for ATTR-CM and Aucatzyl CAR-T for R/R B-ALL
NICE has issued two major decisions: recommending vutrisiran for adult ATTR-CM and approving Aucatzyl CAR-T for relapsed or refractory B-ALL in adults.
By therapy area
CMS Sets New Medicare 2026 Rates Across Five Innovation Categories
What the New Medicare 2026 Rates Mean for Access and Adoption The U.S. Centers for Medicare & Medicaid Services (CMS) has delivered a rare cluster of reimbursement decisions that collectively mark one of the most significant access-defining weeks of 2025. Spanning neuromodulation, molecular diagnostics, AI imaging, autoimmune disease therapy, and oncology support care, the rulings … Read more
NICE Issues New Updates on AI Cancer Detection, Sepsis Care, and Breast Cancer Drug Appraisal
NICE has published three updates spanning diagnostics, acute care, and oncology: conditional support for AI tools that detect bowel cancer polyps, new sepsis guidelines emphasizing tailored treatment, and the termination of a trastuzumab deruxtecan appraisal after no company evidence submission.
B. Braun to Pay $38.5M in DOJ Settlement Over Allegedly Faulty Knee Implant and False Claims
The DOJ has finalized a $38.5 million settlement with B. Braun’s Aesculap unit over allegations involving an early-failing knee implant that triggered false claims to Medicare and Medicaid.
NICE Expands Cancer and Dermatology Options With Three Major Recommendations Across DLBCL, Myeloma, and Chronic Hand Eczema
NICE has issued three major recommendations expanding access to Columvi-GemOx for DLBCL, talquetamab for relapsed myeloma, and delgocitinib for chronic hand eczema.
J&J’s $3B Halda Deal Sets Up $50B Oncology Push
J&J is acquiring Halda Therapeutics for $3.05B, gaining a precision prostate cancer therapy and a breakthrough induced-proximity platform.
ABL Bio’s Grabody lands record heigh $2.6B deal with Lilly
ABL Bio has signed a major license and research collaboration with Eli Lilly worth up to $2.602 billion, granting access to its Grabody bispecific platform.
Cidara Therapeutics Stock sky-Rockets on $9B Merck buyout
Merck’s $9.2 billion acquisition of Cidara brings CD388, a Phase 3 long-acting influenza antiviral, into its pipeline while adding the Cloudbreak® drug-Fc conjugate platform for future oncology and infectious-disease programs.
Spain Expands Newborn Screening Portfolio and Launches National Asbestos Injury Certification in Dual Public Health Overhaul
Spanish health official displays a Ministry of Health certificate for asbestos-related injury, as Spain rolls out its new national certification system alongside expanded neonatal screening reforms. (Editorial illustration.) CISNS approves sweeping updates to neonatal diagnostics and formalizes a nationwide system to certify asbestos-related disease for compensation Spain’s Interterritorial Council of the National Health System (CISNS) … Read more
TLV Endorses Keytruda Combo for Advanced Cervical Cancer with Cost-Effectiveness Caveats
Sweden’s TLV has published its health economic assessment of Merck’s Keytruda for locally advanced cervical cancer, finding clear efficacy benefits when added to chemoradiation. However, the agency warns that cost-effectiveness hinges on price transparency and real-world survival durability.